Biomarkers in Bone Marrow Samples From Patients With Acute Myeloid Leukemia
|ClinicalTrials.gov Identifier: NCT01251159|
Recruitment Status : Completed
First Posted : December 1, 2010
Last Update Posted : May 17, 2017
RATIONALE: Studying samples of bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This laboratory study is studying bone marrow samples from patients with acute myeloid leukemia.
|Condition or disease||Intervention/treatment|
|Leukemia||Genetic: mutation analysis Genetic: polymerase chain reaction Other: immunologic technique Other: laboratory biomarker analysis|
- To rigorously examine fractionated hematopoietic stem and progenitor cells from patients with acute myeloid leukemia (AML).
- To define somatic mutations occurring in de novo AML, including the FLT3-ITD, CEBPA, NPM1, TET2, ASXL1, IDH1, and IDH2 mutations.
- To examine what cellular compartments (LT-HSC, ST-HSC, CMP, GMP, and MEP) contain the selected mutations and in what order those mutations occur.
OUTLINE: Archived bone marrow specimens are analyzed for sequencing and detection of mutations by Sanger-based resequencing of PCR amplicons. Results are then compared with the results of age-matched healthy controls.
|Study Type :||Observational|
|Actual Enrollment :||30 participants|
|Official Title:||Somatic Mutations in Stem and Progenitor Cells in AML|
|Actual Study Start Date :||May 15, 2009|
|Primary Completion Date :||June 15, 2009|
|Study Completion Date :||June 15, 2009|
- Define somatic mutations occurring in de novo AML [ Time Frame: 1 month ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01251159
|Principal Investigator:||Ulrich G. Steidl, MD, BS||Albert Einstein College of Medicine, Inc.|